Highlights
- •With several treatments available, families with a child with SMA are faced with challenging decisions.
- •In order to make informed decisions, families need to understand the full picture of the disease, including the patient perspective on quality of life.
- •A transparent discussion about the range of potential outcomes of different treatments, followed by shared decision-making is essential.
- •Predictive factors for treatment outcomes remain unclear, therefore potential treatment benefit must be assessed on an individual level.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Paediatric NeurologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy.Eur. J. Paediatr. Neurol. 2020; https://doi.org/10.1016/j.ejpn.2020.07.001
- Gene therapy for spinal muscular atrophy: Solomon's consensus in Covid times.Eur. J. Paediatr. Neurol. 2020; https://doi.org/10.1016/j.ejpn.2020.08.005
- Self-reported quality of life has no correlation with functional status in children and adolescents with spinal muscular atrophy.Eur. J. Paediatr. Neurol. 2011; 15: 36-39https://doi.org/10.1016/j.ejpn.2010.07.003
N. Gusset, et al., Understanding European Patient Expectations towards Current Therapeutic Development in Spinal Muscular Atrophy (submitted).
Article info
Publication history
Published online: December 14, 2020
Accepted:
November 20,
2020
Received:
September 28,
2020
Identification
Copyright
© 2020 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Response to letter: A decision for life – Treatment decisions in newly diagnosed families with spinal muscular atrophyEuropean Journal of Paediatric NeurologyVol. 30
- Previewwe highly appreciate the comment by Gusset et al. [1] on our ad-hoc consensus statement [2], as input from patient organisations is instrumental to ensure that patients and their families remain in the focus of the debate. We fully support the demand of the authors for data-driven education, transparent communication to families and patients, and a balanced public discussion in the context of new available treatments for spinal muscular atrophy ( SMA ).
- Full-Text
- Preview
